Arşiv logosu
  • Türkçe
  • English
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
Arşiv logosu
  • Koleksiyonlar
  • DSpace İçeriği
  • Analiz
  • Talep/Soru
  • Türkçe
  • English
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
  1. Ana Sayfa
  2. Yazara Göre Listele

Yazar "Kucukerdonmez, Cem" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
  • Küçük Resim Yok
    Öğe
    Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?
    (IJO PRESS, 2014) Karalezli, Aylin; Kucukerdonmez, Cem; Akova, Yonca A.; Koktekir, Bengu Ekinci
    AIM: To assess the effect of topical bevacizumab use on postoperative pterygium recurrence in eyes who underwent pterygium excision with limbal -conjunctival autograft transplantation (LCAT). METHODS: eighty -eight eyes of 88 patients with primary pterygium were included. Pterygia were graded preoperatively from type 1 to type 3 (type 1 atrophic, type 3 inflamed) according to the inflammatory status. The eyes were preoperatively randomized to receive topical steroid and antibiotic treatment (group 1, 46 eyes) and additional topical bevacizumab (5 mg/mL; group 2, 42 eyes) in the postoperative period. All eyes underwent pterygium excision and LCAT. Medications were tapered and discontinued at one month. Postoperative complications and recurrence rates were recorded. RESULTS: The mean follow -up duration was 29.3 +/- 4.2mo (24-52mo) and 28.5 +/- 3.4 (24-48mo) in group 1 and 2, respectively (P>0.05). There were no statistically significant differences regarding the age or gender between groups (P>0.05). Also, the difference between groups with respect to pterygium type was not significant. During the follow -up period, recurrence developed in 2 eyes (4.3%) in group 1, whereas in one eye (2.4%) in group 2. No statistically significant difference between groups was found in recurrence rates (P>0.05). No re-operation for recurrence was necessary during the follow-up period in both groups. CONCLUSION: Topical bevacizumab seems to have no additonal effect on pterygium recurrence after LCAT.
  • Küçük Resim Yok
    Öğe
    Evaluation of choroidal thickness using spectral-domain optical coherence tomography in patients with migraine: a comparative study
    (SAGE PUBLICATIONS LTD, 2015) Karalezli, Aylin; Celik, Guner; Koktekir, Bengu Ekinci; Kucukerdonmez, Cem
    Purpose: To assess choroidal thickness in patients with migraine and compare them with healthy controls, using spectral-domain optical coherence tomography (OCT). Methods: In this prospective case-control study, choroidal thicknesses of 20 newly diagnosed migraine patients and 20 age-and sex-matched healthy subjects were measured using a high-speed, high-resolution frequency domain (FD) OCT device (lambda = 840 nm, 26.000 A-scans/s, 5 mu m axial resolution). All patients underwent a complete ophthalmic examination before the measurements. OCT measurements were taken at the same time of day (9: 00 AM), in order to minimize the effects of diurnal variation. Results: There was a statistically significant difference in median choroidal thickness between the migraine patients (277.00 [interquartile range (IQR) 85.75] mu m) and controls (301.00 [IQR 90.50] mu m) (p = 0.012). There were significant differences at all measurement points (p<0.05 for all). Conclusions: The decreased choroidal thickness of patients with migraine might be related to the vascular pathology of the disease. Further studies are needed to evaluate the etiopathologic relationship between choroidal thickness and migraine.

| Selçuk Üniversitesi | Kütüphane | Açık Erişim Politikası | Rehber | OAI-PMH |

Bu site Creative Commons Alıntı-Gayri Ticari-Türetilemez 4.0 Uluslararası Lisansı ile korunmaktadır.


Selçuk Üniversitesi Kütüphane ve Dokümantasyon Daire Başkanlığı, Konya, TÜRKİYE
İçerikte herhangi bir hata görürseniz lütfen bize bildirin

DSpace 7.6.1, Powered by İdeal DSpace

DSpace yazılımı telif hakkı © 2002-2025 LYRASIS

  • Çerez Ayarları
  • Gizlilik Politikası
  • Son Kullanıcı Sözleşmesi
  • Geri Bildirim